Glytec, a leading diabetes and insulin management software company, has partnered with pharmaceutical giant Roche to integrate Glytec’s software with Roche’s cobas pulse system. This collaboration will be rolled out in both the U.S. and global markets, aiming to improve diabetes management in hospital settings. Roche’s cobas pulse is known for its advanced point-of-care smart-device capabilities and lab-like accuracy, which greatly reduces the need for repeated testing across various patient demographics, including neonates and intensive care patients.
Glytec’s pivotal technology in this partnership is its FDA-cleared insulin-dosing decision support software, Glucommander. This system plays a crucial role in inpatient diabetes treatment by helping healthcare providers optimize glycemic control strategies, thus enhancing patient outcomes. The combined expertise and reach of Roche and Glytec are expected to improve patient safety, increase the cost-effectiveness of care, and foster better overall health outcomes.
Robby Booth, Glytec’s cofounder and chief strategy officer, emphasized the global impact of diabetes, which significantly complicates hospital diabetes management and affects patient outcomes across the world. He expressed pride in the partnership, highlighting its potential to address pressing healthcare challenges and enhance life quality for people worldwide.
This partnership aligns with Glytec’s broader strategic goals, which have recently included supporting CMS’s new mandatory reporting requirements, aimed at improving measures related to hyperglycemia and hypoglycemia. This initiative particularly targets enhancement of diabetes care in rural and underserved communities across the U.S., dovetailing with broader value-based care efforts.
Additionally, Glytec has been actively forming partnerships to expand the reach and efficacy of its technologies. In June, the company announced a strategic collaboration with Major Health Partners, a community-based hospital in Shelbyville, Indiana. This partnership focuses on incorporating Glucommander to standardize insulin titration and minimize the risks associated with severe hypoglycemia.
Moreover, in May, Glytec partnered with the Cleveland Clinic to implement its insulin management software at UH Cleveland Medical Center. This software uses evidence-based algorithms and dynamic data analysis to customize insulin dosing for patients who require it, further exemplifying the company’s push towards precision in diabetes management.
Reflecting its growth trajectory and market confidence, in 2021, Glytec secured $21 million in funding from entities such as Silicon Valley Bank, Savitr Capital, and other private investors. This financial boost comprised $9 million in debt financing from SVB and $12 million in equity investments led by Savitr, bolstering Glytec’s capabilities and paving the way for future innovations and partnerships.
This series of strategic moves and collaborations underscores Glytec’s commitment to revolutionizing the field of insulin management and diabetes care, significantly impacting how these health conditions are managed in clinical settings both in the U.S. and globally. By partnering with other leaders in healthcare and technology, Glytec is set to offer more robust and finely tuned solutions that promise better health outcomes for widespread and diverse populations affected by diabetes.
#Glytec #expands #partnership #Roche #hospital #diabetes #management
